De­sert­ed by Astel­las and Mer­ck, lit­tle Cor­re­vio still can't win over FDA pan­el con­cerned with its AFib drug's safe­ty

When the FDA spurned Astel­las’ pitch for atri­al fib­ril­la­tion drug ver­nakalant in 2008, reg­u­la­tors made it abun­dant­ly clear that it wasn’t the ef­fi­ca­cy they had …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.